Q3 2024 saw Coegin Pharma secure key development and commercialization agreements, strengthen its financial position with SEK 17.5 million from warrant exercises, and advance its cosmetic and biotech pipelines toward product launches in 2025–2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.